James Martin Johnston MD

Pediatric Hematology & Oncology•Reno, NV

Associate Professor, Mercer University School of Medicine

Join to View Full Profile

75 Pringle WaySte 505Reno, NV 89502
Phone+1 775-982-5000
Fax+1 775-982-3900

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Pediatric Hematology/Oncology, 1988 - 1991
University of Utah HealthResidency, Pediatrics, 1984 - 1987
Duke University School of MedicineClass of 1984

Certifications & Licensure

TX State Medical License 2024 - 2026
NV State Medical License 1988 - 2025
WI State Medical License 1994 - 2025
GA State Medical License 2007 - 2019
ID State Medical License 1999 - 2008
UT State Medical License 1985 - 1994
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
ACTIVE_NOT_RECRUITING
PHASE3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
ACTIVE_NOT_RECRUITING
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
ACTIVE_NOT_RECRUITING
PHASE3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
ACTIVE_NOT_RECRUITING
PHASE3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
ACTIVE_NOT_RECRUITING
PHASE3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Join now to see all

Publications & Presentations

PubMed

3 citations
Histologic maturation of cerebral neuroblastoma following conventional chemotherapy.
Alan Bidgoli, Roger E. McLendon, J. Martin Johnston
Pediatric Blood & Cancer. 2021-03-30